O8 OXMINT – 2 years of a novel multi-disciplinary service for metastatic bone disease

Le résumé fourni par la source

Local data suggests 20-27% of patients known to the Oxfordshire Palliative Care Service have metastatic bone disease. Literature calls for a Multi-Disciplinary approach to support and co-ordinate care in patients with metastatic bone disease but there is no clear definition of what components the team should entail. Until 2023 there had been no clear established pathway for referral, discussion and management of symptomatic bone metastases in Oxfordshire. This had led to a fragmented and inequitable service for patients with management plans often guided by individual clinician experience or network OxMINT (Oxford Metastatic Intervention Team) is a novel and innovative service to provide a safe and effective clinical forum to support the ever-growing patient population with metastatic spinal disease. The service was designed and implemented by Dr Victoria Bradley, Clinical Lead for and Consultant in Palliative Medicine in 2023. The service aims are managing symptoms, maintaining functional status and quality of life with expert synchronous and multi-disciplinary input from; Orthopaedics (general and spine), Radiology including interventional radiology, Interventional pain (anaesthetics), Clinical Oncology, Palliative Medicine, Neurosurgery and Psychological Medicine The OxMINT service has now reviewed over 300 patients with an active intervention rate of 76% and re-discussion rate of 4.6%. To date, 28% of referrals are in the last 3 months of life (range 0-14m) correlating with our recommendation for Best Supportive Care in 21% of patients. Our patient demographics are heterogenous and reflect national cancer data: age range 16-96 years, gender split 58% females: 42% males with over 13 different primary tumour sites represented. OxMINT Patients are living more than 24 months beyond referral. Recommendations for Surgery, Interventional Radiology and/or Radiotherapy in the remaining 79% supports function and pain control, has a complication rate of <10% and creates a new gold-standard of care to drive optimal patient-led outcomes and personalised medicine.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.